Position in ENGN
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$11,538,940
New position
Shares Held
6,669,908
first reported quarter
Ownership
9.96%
of shares outstanding
% of Portfolio
6.59%
of 13F equity value
Holder Rank
#2
of 60 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026BML Capital Management, LLC holds $130,180,167 across 10 Biotechnology names. ENGN ranks #3 (8.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ACRS |
Aclaris Therapeutics, Inc.
|
11,975,000 | $63,347,750 | |
| 2 | AVIR |
Atea Pharmaceuticals, Inc.
|
6,952,330 | $32,328,334 | |
| 3 | ENGN |
enGene Therapeutics Inc.
This page
|
6,669,908 | $11,538,940 | |
| 4 | PMVP |
PMV Pharmaceuticals, Inc.
|
5,330,000 | $7,142,200 | |
| 5 | TIL |
Instil Bio, Inc.
|
645,600 | $4,964,664 | |
| 6 | ORMP |
Oramed Pharmaceuticals Inc.
|
866,269 | $4,166,753 | |
| 7 | JANX |
Janux Therapeutics, Inc.
|
154,961 | $2,380,200 | |
| 8 | PLRX |
Pliant Therapeutics, Inc.
|
1,546,137 | $1,762,596 |
All Filings in ENGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,538,940 | 6,669,908 | Shares | Sole | 2026-08-07 | |
| No filing history on record for this holder in this stock. | ||||||